Navigation Links
The Novel Oral Anticoagulants Will Continue to Drive Growth in the Atrial Fibrillation Drug Market

BURLINGTON, Mass., Dec. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the atrial fibrillation drug market will experience continued growth through the rest of the decade, increasing from $3.4 billion in 2012 to $8.6 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. However, generic entry of Boehringer Ingelheim's Pradaxa and Bayer/Janssen's Xarelto will result in contraction of the atrial fibrillation market in the latter part of the 2012 to 2022 forecast period, with the market contracting to $8.1 billion in 2022.


The Pharmacor advisory service entitled Atrial Fibrillation, which will be published in the days ahead, finds that the novel oral anticoagulants developed for the prevention of stroke in atrial fibrillation patients will continue to drive market growth, accounting for approximately 70 percent market share in 2022. Despite a slow start following its 2013 launch, Bristol-Myers Squibb/Pfizer's Eliquis is expected to be the sales-leading anticoagulant and will garner more than $2.7 billion in 2022. The use of the new anticoagulants will result in a steep decline in sales of warfarin (Bristol-Myers Squibb's Coumadin, Eisai's Warfarin, generics) and other currently available vitamin K antagonists. The anticipated launch of Armetheon's tecarfarin as an anticoagulant therapy for atrial fibrillation patients with mechanical heart valves in the United States will see vitamin K antagonists remain a notable presence in the atrial fibrillation drug market.

The report also reveals that ChanRx's oral cardioversion agent vanoxerine will become the sales-leading antiarrhythmic drug during the forecast period, despite only launching in 2018. Vanoxerine's high efficacy, combined with its strong safety profile, will ensure strong uptake both as a cardioversion agent and as a pill-in-the-pocket therapy.

"Despite initial poor uptake following its launch, we forecast that Eliquis will become the market leader owing to its superior clinical trial data. Eliquis remains the only agent to demonstrate increased efficacy and lower rates of major bleeding versus warfarin," said Decision Resources Analyst Eamonn O'Connor, Ph.D. "Continued strong uptake of Bayer/Janssen's Xarelto, due largely to its once-daily dosing, will see Xarelto become the second best-selling agent with peak-year sales in excess of $2 billion prior to its patent expiration in the United States in 2021."

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Announces Acquisition of Rights to Novel LAMA Respiratory Compound from Pfizer
2. BioLineRx Enters Clinic with Novel Treatment for Celiac Disease
3. ARGX-110, a Novel Anti-CD70 Antibody, Meets Translational Development Goals in Dose Escalation Part of Phase Ib Cancer Study
4. The Market for Non-Small-Cell Lung Cancer (NSCLC) Will Grow to $7 Billion in 2022, Fuelled by the Entry of Twelve Novel Agents
5. The Acute Coronary Syndrome 12-Month Posthospital Market Will Double by 2022, Driven by the Uptake of Novel Lipid Modifying Agents
6. Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products
7. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
8. Opportunity Exists in the U.S. for Novel Agents in Crohns Disease and Ulcerative Colitis, Owing to Discontinued Use of Leading Anti-TNF Agents Driven by Efficacy Failures
9. Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes
10. Bavarian Nordic, the international novel cancer and infectious disease vaccines focused biotech, now covered by Edison.
11. FLAG Therapeutics and Duquesne University Announce Exclusive Worldwide Licensing Agreement for Novel, Dual-action Targeted Oncology Compounds
Post Your Comments:
(Date:11/25/2015)... Research and Markets ( ) has ... Global Forecast to 2020" report to their offering. ... 37.21% of the total market share in 2014. The ... is projected to growth at the highest CAGR between ... to the fast growing water, industrial gas treatment, pharmaceutical, ...
(Date:11/25/2015)... , Frankreich, November 25, 2015 ... bekanntgegeben, dass sie eine Lizenz für das Patent über ... CNRS, UCBL und ENS-Lyon innehaben, an Enyo Pharma vergeben ... FUI AAP8 ins Leben gerufenen und von Edelris gemeinsam ... FXR als ein Behandlungsziel für HBV identifiziert, und es ...
(Date:11/25/2015)... November 25, 2015 ... addition of the  "Global Drug Device ... to their offering.  --> ... of the  "Global Drug Device Combination ... their offering.  --> Research ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 25, 2015 , ... Since its launch in 2012, the ... stem cell therapies to patients with chronic degenerative medical conditions. Now, the U.S. ... Trademark (RTM). , Organizations are required to hold a registered trademark in order ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Students and ... were awarded to winners of the Create Real Impact awards. California Casualty ... to help stem the tide of distracted and reckless driving, the number one killer ...
(Date:11/25/2015)... ... 25, 2015 , ... Bunion Bootie , the newest ... of the early holiday shopping season. Starting Wednesday November 25th, Bunion Booties are ... Friday promotional pricing is in addition to any automatic discounts applied when buying ...
(Date:11/24/2015)... , ... November 25, 2015 , ... ... monitoring. Their Care Plan software creates an agreement between the practice owner ... plan, including financial, scheduling, monitoring, notification, and projections. Click here ...
(Date:11/24/2015)... ... November 24, 2015 , ... Eric C. Seidel, ... many benefits of the revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser ... used by a dentist in Gettysburg, PA . From routine visits to ...
Breaking Medicine News(10 mins):